Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Protein aggregates (Neurodegenerative diseases)
- Amyotrophic Lateral Sclerosis (ALS)
- Aggregated protein(s) in ALS
- Ubiquitinated TDP-43 in FLD and ALS
- TDP-43 mutations linked to ALS
- What are the cellular pathways affected?
- Which biological model to choose?
- TDP-43 aggregation and toxicity in yeast cells
- Yeast screens to define TDP-43 toxicity in ALS
- Yeast screen for modifiers of TDP-43 toxicity
- Comparing hits from TDP-43 and alpha-synuclein
- 41 verified TDP-43 suppressors and enhancers
- PBP1 overexpression enhances TDP-43 toxicity
- PBP1 deletion suppresses TDP-43 toxicity
- Ataxin-2 is a polyglutamine disease gene (1)
- Ataxin-2 modulates TDP-43 toxicity (1)
- Ataxin-2 modulates TDP-43 toxicity (2)
- Perturbed ataxin-2 localization in motor neurons
- Ataxin-2 is a polyglutamine disease gene (2)
- The ataxin-2 gene
- Ataxin-2 and ALS?
- Are polyQ repeats in ataxin-2 linked to ALS?
- Intermediate-length ataxin-2 polyQ expansions
- Ataxin-2 is an ALS disease gene
- Stress granules in ALS pathogenesis (1)
- Ataxin-2 reduction & stress granule maturation
- Ataxin-2 and TDP-43 in ALS
- Lowering ataxin-2 levels
- Reducing ataxin-2 levels extends survival
- Reducing ataxin-2 improves motor performance
- Lowering ataxin-2 eliminates TDP-43 pathology
- Antisense oligonucleotides (ASOs) & ataxin-2
- Ataxin-2 ASO treatment extends survival
- Pathological inclusions in ALS and FTD
- Towards ataxin-2 as an ALS therapeutic target
- Other genes from yeast screen
- Another RNA-binding protein linked to ALS
- FUS aggregation and toxicity in yeast
- Rethinking ALS: The FUS about TDP-43
- More TDP-43 and FUS-like genes
- 35 RNA-binding proteins aggregate and are toxic
- Mammalian prions
- Yeast prions
- FUS and TDP-43 prion-like domains
- Prion-like domains (1)
- Prion-like domains (2)
- Just the tip of the iceberg
- Expanding the RNA-binding protein landscape
- Stress granules in ALS pathogenesis (2)
- Stress granules in ALS pathogenesis (3)
- Can we use yeast to study other ALS genes too?
- Genome wide association studies
- Manhattan plot
- Published GWAS through 07/2012
- GWAS links 9p21 to ALS (1)
- GWAS links 9p21 to ALS (2)
- GWAS links 9p21 to ALS (3)
- GWAS links 9p21 to ALS (4)
- How do GGGGCC expansions cause FTLD/ALS?
- RAN translation in Huntington disease
- C9orf72 sense and antisense transcripts
- RAN translation in yeast
- Toxicity of RNA & dipeptide repeat proteins (1)
- Arginine-rich C9orf72 dipeptides: toxic in yeast
- C9orf72 dipeptides: toxic in Drosophila
- Yeast screens of C9orf72 dipeptide toxicity
- C9orf72 mutation impairs nuclear transport
- Toxicity of RNA & dipeptide repeat proteins (2)
- Nucleo-cytoplasmic transport impairments in ALS
- Acknowledgments
Topics Covered
- Amyotrophic lateral sclerosis (ALS)
- Genetic causes of ALS
- Role of RNA-binding proteins and stress granules in ALS pathogenesis
- Emerging class of RNA-binding proteins with prion-like domains in neurodegenerative disease
- Mechanisms by which C9ORF72 mutations cause ALS
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Gitler, A.D. (2017, November 30). Expanding roles of RNA-binding proteins in neurodegenerative diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 24, 2024, from https://doi.org/10.69645/TTSG4529.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Aaron D. Gitler has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: ALS and Other Motor Neuron Disorders
Transcript
Please wait while the transcript is being prepared...
0:00
The title of my talk is
Expanding Roles of RNA-Binding Proteins in Neurodegenerative Diseases.
My name is Aaron Gitler;
I'm a professor in the Department of Genetics at Stanford University School of Medicine.
0:14
My laboratory is interested in the mechanisms of human neurodegenerative diseases.
These diseases include Alzheimer's disease,
Parkinson's disease, Huntington's and ALS.
As our population continues to age,
these diseases are increasing in prevalence.
They have several different clinical presentations, ranging from
memory loss in Alzheimer's disease to movement impairments in Parkinson's disease.
Despite these differences in clinical presentation,
there's a common theme that unites
all neurodegenerative diseases - and this is protein misfolding.
Proteins accumulate and aggregate in the brains of patients affected with these diseases,
and my laboratory is trying to understand the cellular pathways affected,
when misfolded human disease proteins aggregate.
1:03
Today, I'm going to be talking about
one neurodegenerative disease called Amyotrophic Lateral Sclerosis,
and using it as an example of
how we study protein misfolding and how
RNA-binding proteins play an important role in this disease.
Amyotrophic Lateral Sclerosis, also known as ALS,
in the United States known as Lou Gehrig disease,
after the famous New York Yankees first baseman,
and in Europe as Motor Neurone disease.
This is a disease that affects adults in mid-to-late life,
and is associated with progressive muscle weakness and
eventually muscle loss caused by
a selective loss of motor neurons in the brain-stem and spinal cord.
Loss of these motor neurons leads to muscle weakness,
paralysis and then ultimately death,
typically two to five years after onset.
ALS, like other neurodegenerative diseases comes in a sporadic form or a familial form.
About 90% of ALS cases are sporadic and 10% are familial.
Even though the familial forms are rarer,
they've played important roles in helping us to understand the causes of ALS,
because specific genes can be identified that when mutated cause familial ALS,
and defining those genes can provide insight into cellular pathways that are affected.
The first gene identified that causes ALS when mutated
is SOD1 which encodes the enzyme superoxide dismutase 1.
These mutations affect only about 2% of ALS cases,
suggesting there are additional genetic contributors to be discovered.
Hide